ReleaseWire

Cornerstone BioPharma (“Cornerstone”) of Cary, North Carolina, and J-Med Pharmaceuticals (“J-Med”) of Boston, Massachusetts, today announced that they have settled pending patent litigation with Sovereign Pharmaceuticals, Ltd., (“Sovereign”) of Fort Worth, Texas, in connection with U.S. Patent No. 6,270,796 (“the ‘796 patent”). The litigation was brought by the patent owner J-Med and licensee Cornerstone, who markets and sells the AlleRx™ Dose Pack.

Cornerstone BioPharma™, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced the company has obtained exclusive U.S. licensing rights from leading Japanese pharmaceutical company Meiji Seika Kaisha for Spectracef (cefditoren pivoxil).

Gentris Corporation (Gentris), a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, today announced the appointment of Andrea Gaedigk, M.S., Ph.D. to the company’s Scientific Advisory Board.

Gentris Corporation (Gentris), a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, today announced that the company has completed an FDA 510(k) submission for six Human Genomic DNA Reference Controls for the Cytochrome P450 2D6 gene (CYP2D6). Under the GentriSure™ brand, the six products include: CYP2D6 *4A/*2AxN, CYP2D6 *29/*2AxN, CYP2D6 *2M/*17, CYP2D6 *3A/*4A, CYP2D6 *6B/*41 and CYP2D6 *1/*5 Human Genomic DNA Reference Controls.

Thailand will host BioAsia 2007, the first international trade exhibition and conference for biotechnology in Bangkok from November 7 to 9, 2007 at Queen Sirikit National Convention Center (QSNCC), expecting the biggest convergence of biotech enthusiasts in food, agriculture, health, industrial and environmental sectors from all over all the world.

The Ephrine Plus® energy diet pill is known to retailers as one of their most popular fast weight loss products. Drug and convenience stores have traditionally been the principle source for dieters to find their favorite, most effective energy diet pill. These days, they can now buy Ephrine Plus® online, as well.

DMD Pharmaceuticals announces its new Hoodia Gordonii diet pill, Trim-U™, which has been formulated to help dieters reach their optimum weight loss goals quickly. Both an appetite suppressant and energizer, the Trim-U™ Hoodia diet supplement contains 250 mg of Hoodia Gordonii, the renowned ancient appetite suppressant.

A Psychiatric Drug Adverse Reaction Report Hot Line could lead to thousands more suits against psychiatrists forcing these drugs onto patients, the Citizens Commission on Human Rights (CCHR) announced.

Specialty Pharma magazine has published an article on Patent Landscape Mapping for Pharmaceutical applications authored by David A. Sacks and Eve Y. Zhou of IP Partner LLC.

The third Global Forum on Pharmaceutical Anti Counterfeiting, organised by Reconnaissance International, has been announced for March 13-17 2007. The hotly-anticipated event will focus on the interface between the different stakeholders, including manufacturers, service providers and health care providers.

David A. Sacks has joined IP Partner LLC as Vice President of Licensing specializing the management of intellectual property management for the pharmaceutical industry.

The FDA reported that in the four year period between 1999 and 2003, there were twenty-five deaths in persons using Attention Deficit Hyperactivity Disorder (ADHD) drugs.

The FDA reported that in the four year period between 1999 and 2003, there were twenty-five deaths in persons using Attention Deficit Hyperactivity Disorder (ADHD) drugs.

According to the New England Journal of Medicine, Infants had six times the expected risk of developing the lung disorder which resulted from mothers who took the drugs in the second half of pregnancy.

Experts estimate that only 1% to 10% of serious drug reactions are reported to the FDA, so the deaths and serious adverse effects are undoubtedly much higher.

Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment of conditions and diseases affecting pediatrics and the healthy growth of children are vital to providing a solid foundation for healthy adults in the future.